The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Cited by
Sorted by citations
Items 501–600 of 747
Commentary: Using human genetics to guide the repurposing of medicines
Bovijn, J., Censin, J. C., Lindgren, C. M., & Holmes, M. V. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa015 · Cited by 4
Carter, P., Vithayathil, M. K., Kar, S., Potluri, R., Mason, A. M., Larsson, S. C., & Burgess, S. (2020) · medRxiv · doi:10.1101/2020.02.28.20028902 · Cited by 5
Editorial comment: when Mendelian randomization goes astray
Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000735 · Cited by 5
Hu, E., & Wan, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001464 · Cited by 4
CETP Inhibitors: Back With a New Target
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2026) · Circulation Research · doi:10.1161/circresaha.125.327271 · Cited by 4
Unravelling Osteoporosis: Key Genes and Potential Therapies
Fu, H., Wu, Y., Lv, H., Qiu, L., Hu, W.-F., Wu, H.-Y., Qian, J., Liang, X., Wang, X., & Xu, G. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70759 · Cited by 4
Repurposing statin treatment for the prevention of gallstone disease.
Rønborg, S. N., Qayyum, F., Lauridsen, B., Frikke-Schmidt, R., Nordestgaard, B., Christoffersen, M., & Tybjærg-Hansen, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120507 · Cited by 5
Luo, P., & Yu, X. (2024) · Liver International · doi:10.1111/liv.15905 · Cited by 3
Fu, L., Liu, Q., Cheng, H., Zhao, X., Xiong, J., & Mi, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038857 · Cited by 4
Gong, Z., Wu, D., Ku, Y., Zou, C., Qiu, L., Hao, X., & Liu, L. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03527-x · Cited by 4
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
Legault, M., Hartford, J., Arsenault, B. J., Yang, A. Y., & Pineau, J. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.04.010 · Cited by 7
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease
Hoffmann, M. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0996-5 · Cited by 4
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Nicholls, S. J. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.3.2 · Cited by 4
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13637 · Cited by 4
Genotype‐driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis
Baumeister, S., Holtfreter, B., Reckelkamm, S. L., Kocher, T., Alayash, Z., Ehmke, B., Baurecht, H., & Nolde, M. (2022) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13719 · Cited by 4
Atreya, M. R., Cvijanovich, N. Z., Fitzgerald, J. C., Weiss, S. L., Bigham, M. T., Jain, P., Schwarz, A. J., Lutfi, R., Nowak, J. E., Allen, G. L., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04535-1 · Cited by 4
Xiao, W., Li, Y., Zhuang, Z., Song, Z., Wang, W., Huang, N., Dong, X. Y., Jia, J., Liu, Z., Zhao, Y., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02133-w · Cited by 4
Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
Rikhi, R. R., & Shapiro, M. D. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02141-3 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
LDL-C Targets in Secondary Prevention: How Low Should We Go?
Bayoumy, K., Gaber, M., Mani, P., Puri, R., Donnellan, E., Cho, L., Clark, D., Martin, S. S., & Elshazly, M. B. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0619-8 · Cited by 4
Pancreatic PCSK9 and its involvement in diabetes
Kockx, M., & Kritharides, L. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.37 · Cited by 4
PCSK9 inhibitors and diabetes mellitus
Vohnout, B., Lisičanová, J., & Havranová, A. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.170 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
Investigational therapies for hypercholesterolemia
TOMKIN, G. H., & Owens, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1315407 · Cited by 4
Usefulness of compounds with monacolin K in a case of statins intolerance
Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., Núñez-Cortés, J. M., & Alvarez-Sala, L. A. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.003 · Cited by 4
PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia
Reeskamp, L. F., Tromp, T. R., & Hovingh, G. K. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319886140 · Cited by 4
Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy
Everett, B. M. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.036 · Cited by 4
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/335877 · Cited by 4
The fat of the matter: lipoprotein effects of dietary fatty acids vary by body weight status
Maki, K. C. (2019) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz166 · Cited by 4
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-15525-4 · Cited by 3
“This approach has also been widely applied to predict likely beneficial effects of drug targets on cardiovascular diseases 13 , neurological diseases 14 and cancers 15 .”
Lembo, M., Trimarco, V., Pacella, D., Izzo, R., Jankauskas, S. S., Piccinocchi, R., Gallo, P., Bardi, L., Piccinocchi, G., Morisco, C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02964-6 · Cited by 4
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective
Hu, D., Deng, X., Feng, M., Zhang, X., He, Q., Wang, T., & Feng, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708701 · Cited by 3
LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship
Merino, J., & Rotter, J. I. (2020) · Diabetes · doi:10.2337/dbi20-0031 · Cited by 3
Gupta, J., & Gupta, R. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221202144813 · Cited by 3
Sun, L., Zhang, Q., Shi, M., Liu, Y., Zhu, Z., Zhang, J., Peng, H. Y., Wang, A., Chen, J., Xu, T., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036544 · Cited by 3
Zhou, Y., Ding, Y., Xu, B., Fei, H., & Wang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-024-82567-5 · Cited by 3
Hwang, S., Karhunen, V., Patel, A., Lockhart, S. M., Carter, P., Whittaker, J. C., & Burgess, S. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf223 · Cited by 3
Cardiology Meets Personalized Lifestyle Medicine.
Bland, J. S. (2017) · PubMed Central · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
Self-citationOgiya, D., Chyra, Z., Verselis, S. J., O'Keefe, M., Cobb, J., Abiatari, I., Talluri, S., Sithara, A. A., Hideshima, T., Chu, M. P., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00791-0 · Cited by 5
Low-density lipoprotein cholesterol levels are associated with first-phase insulin release
CEFALO, C. M. A., Succurro, E., Riccio, A., Marini, M. A., Fiorentino, T. V., Perticone, M., Sciacqua, A., Andreozzi, F., & Sesti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110633 · Cited by 4
Lu, J., Liu, Y., Wang, Z., Zhou, K., Pan, Y., Zhong, S., & Jiang, G. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.07.011 · Cited by 3
Unraveling the molecular crossroads: T2DM and Parkinson’s disease interactions
Liu, T., KONG, X., & Wei, J. (2024) · Biocell · doi:10.32604/biocell.2024.056272 · Cited by 3
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.013 · Cited by 3
LDL-cholesterol reduction in chronic kidney disease: options beyond statins
Goonasekera, M. A., Mafham, M. M., & Haynes, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000628 · Cited by 3
Wardani, I. S. (2023) · Jurnal Penelitian Pendidikan IPA · doi:10.29303/jppipa.v9i9.5274 · Cited by 3
PCSK9 inhibition and diabetes: turning to Mendel for clues
Lee, J.-H., & Hegele, R. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30398-9 · Cited by 3
Leveraging Human Genetics to Understand the Relation of LDL Cholesterol with Type 2 Diabetes
Ingelsson, E., & Knowles, J. W. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.268565 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
Turgeon, R. D., & Pearson, G. J. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170707 · Cited by 5
Faraj, M. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30042-2 · Cited by 3
Malvandi, A. M., Canclini, L., Alliaj, A., Magni, P., Zambon, A., & Catapano, A. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801628 · Cited by 3
Self-citationKAMIR-NIH Investigators, Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., et al. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00476-z · Cited by 3
Zhang, S., Ge, Q., Chen, L., & Chen, K. (2021) · Processes · doi:10.3390/pr9111898 · Cited by 4
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J. M., Sharp, S. A., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/214700 · Cited by 3
Sklar, M. C., dos Santos, C. C., & Lawler, P. R. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003609 · Cited by 3
Lifelong genetically lowered sclerostin and risk of cardiovascular diseasePreprint
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. D. G. M., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/531004 · Cited by 3
Nounu, A., Walker, V. M., & Richmond, R. C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03508-z · Cited by 3
Sobczyk, M. K., Zheng, J., Smith, G. D., & Gaunt, T. R. (2022) · medRxiv · doi:10.1101/2022.04.11.22273633 · Cited by 3
Assessing Long-Term Liver Safety of Statins and PCSK9 Inhibitors Using Human Genetics
Vujković, M. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.10.008 · Cited by 3
Ference, B. A., Ference, T. B., Catapano, A. L., Nicholls, S. J., & Ray, K. K. (2024) · medRxiv · doi:10.1101/2024.06.30.24309740 · Cited by 3
Self-citationHamad, M. A., Muhammad, J. S., Rah, B., Hasan, H. A., Taneera, J., Soofi, A., & Awadallah, S. M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300107 · Cited by 3
Xiao, Y., Jing, D., Zhou, G., Tang, Z., Peng, C., Kuang, Y., Zhu, W., Chen, X. '., Liu, H., & Shen, M. (2023) · Rheumatology · doi:10.1093/rheumatology/kead462 · Cited by 4
Alraddadi, S. I., Almodaimegh, H., Kharbosh, A., Alharbi, H., Fathelrahman, A. I., Alsheikh, M. Y., & Alfehaid, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01587-x · Cited by 3
Takahashi, N., Campbell, K. R., Nakada, T., & Walley, K. R. (2025) · Critical Care Medicine · doi:10.1097/ccm.0000000000006809 · Cited by 2
The Impact of PCSK9 on Diabetic Cardiomyopathy: Mechanisms and Implications
Wang, H., Wang, P., Wang, Y., Du, S., Zhao, J., & Zhang, Z. (2025) · Biomolecules · doi:10.3390/biom15091240 · Cited by 2
Ciofani, J. L., Allahwala, U. K., Ekmejian, A. A., Pepe, S., & Bhindi, R. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.10.005 · Cited by 2
Jin, M., Zhou, Y., Zhao, X., Liu, C., Liu, Z., Liu, S., & Zhenyan, F. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05502-8 · Cited by 2
Zhang, Y., Qu, Y., Luo, Q., Liang, B., Jiang, Q., Zhu, X., Wu, J., & Bao, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1738089 · Cited by 2
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
Abdalwahab, A., Al‐Atta, A., Zaman, A., & Alkhalil, M. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i9.472 · Cited by 2
Zhao, Y., Li, W., Li, W., Tao, H., Li, Y., Wu, B., Wang, X., Zhou, H., & Gao, B. (2022) · BioMed Research International · doi:10.1155/2022/9039377 · Cited by 2
Baudier, C., Fougerousse, F., Asselbergs, F. W., Guedj, M., Michel Komajda, N., Kotecha, D., Lumbers, R. T., Schmidt, A. F., & Tyl, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148931 · Cited by 2
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 4
Lu, F., Li, E., & Yang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1413123 · Cited by 2
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
Moura, F. A., Kamanu, F., Wiviott, S. D., Giugliano, R. P., Udler, M. S., Florez, J. C., Ellinor, P. T., Sabatine, M. S., Ruff, C. T., & Marston, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16123 · Cited by 2
Self-citationHMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study
Miskelly, M. G., Lindqvist, A., Jujić, A., Hamilton, A., Cowan, E., Raikundalia, S., Andersson, A. D., Nergård, B.-J., Giudice, R. D., Kryvokhyzha, D., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf608 · Cited by 1
Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs
Butters, J., Brown, A. D. H., Griffith, L., Kim, H., & Nicholls, S. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0231-6 · Cited by 2
The year 2020 in Atherosclerosis
Binder, C. J., Borén, J., Catapano, A. L., Kronenberg, F., Mallat, Z., Negrini, S., Öörni, K., Raggi, P., & von Eckardstein, A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.013 · Cited by 2
Self-citationFarnier, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.01.02 · Cited by 2
Medication‐based versus target‐based lipid management
Fazio, S., & Shapiro, M. D. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12789 · Cited by 2
Self-citationThe 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
Thanassoulis, G., Grégoire, J. C., & Pearson, G. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.03.003 · Cited by 2
Efficacité et sécurité des inhibiteurs de PCSK9 dans le diabète
Dijk, W., May, C. L., & Cariou, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30044-6 · Cited by 2
Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease
Ndrepepa, G., Cassese, S., Xhepa, E., Fusaro, M., Laugwitz, K., Schunkert, H., & Kastrati, A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.12.044 · Cited by 2
Adverse events to PCSK-9 inhibitors: what is the current evidence?
Floyd, C., & Crook, M. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138746 · Cited by 2
Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings
Wang, D., & Zhang, D. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000441 · Cited by 2
Wang, X., Wen, D., Fang, M., You, C., & Ma, L. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2410286 · Cited by 2
HMGCR and PCSK9 variants and cardiovascular risk
Lim, G. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.204 · Cited by 2
Prinzip der mendelschen Randomisierung und Anwendung in der kardiovaskulären Medizin
Katzmann, J. L., Ference, B. A., & Laufs, U. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0328-z · Cited by 2
Self-citationButty, A., Gencer, B., Koskinas, K. C., Carballo, D., Räber, L., Klingenberg, R., Matter, C. M., Lüscher, T. F., Windecker, S., Müller, O., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.012 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Laufs, U. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx054 · Cited by 2
So, H., Chau, C. K., & Zhao, K. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170241 · Cited by 2
Clinical benefits of evolocumab appear less than hoped – Authors' reply
Giugliano, R. P., KEECH, A. C., Sever, P. S., Pedersen, T. R., & Sabatine, M. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30529-4 · Cited by 2
Self-citationCarter, A. R., Borges, M. C., Benn, M., Tybjærg‐Hansen, A., Smith, G. D., Nordestgaard, B. G., & Lawlor, D. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/303313 · Cited by 2
Leyden, G. M., Gaunt, T. R., & Richardson, T. G. (2020) · medRxiv · doi:10.1101/2020.02.16.20023010 · Cited by 2
Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., Smith, G. D., Gaunt, T. R., & Richardson, T. G. (2022) · medRxiv · doi:10.1101/2022.04.18.22274003 · Cited by 2
Baya, N. A., Lassen, F. H., Hill, B., Venkatesh, S. S., Currant, H., Lindgren, C. M., & Palmer, D. S. (2025) · medRxiv · doi:10.64898/2025.12.30.25343229 · Cited by 2
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
